424 related articles for article (PubMed ID: 30742242)
1. Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives.
Rhee CK; Yoshisue H; Lad R
Adv Ther; 2019 Mar; 36(3):495-519. PubMed ID: 30742242
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β
Wang MT; Lai JH; Huang YL; Liou JT; Cheng SH; Lin CW; Pan HY; Hsu YJ; Tsai CL
Chest; 2021 Oct; 160(4):1255-1270. PubMed ID: 34023320
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice - Results of the Non-Interventional DETECT Study.
Plate T; Friedrich FW; Beier J
Int J Chron Obstruct Pulmon Dis; 2020; 15():1335-1347. PubMed ID: 32606643
[TBL] [Abstract][Full Text] [Related]
4. Dual bronchodilator therapy for chronic obstructive pulmonary disease: evidence for the efficacy and Safety of fixed dose combination treatments in the setting of recent guideline updates.
Deas SD; Huprikar N
Curr Opin Pulm Med; 2018 Mar; 24(2):130-137. PubMed ID: 29206657
[TBL] [Abstract][Full Text] [Related]
5. Comparing Clinical Outcomes of Tiotropium/Olodaterol, Umeclidinium/Vilanterol, and Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Patients with Chronic Obstructive Pulmonary Disease in Taiwan: A Multicenter Cohort Study.
Hsieh MJ; Chen NH; Cheng SL; Tao CW; Wei YF; Wu YK; Chan MC; Liu SF; Hsu WH; Yang TM; Lin MS; Liu CL; Kuo PH; Tsai YH
Int J Chron Obstruct Pulmon Dis; 2022; 17():967-976. PubMed ID: 35510163
[TBL] [Abstract][Full Text] [Related]
6. Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.
Ismaila AS; Haeussler K; Czira A; Tongbram V; Malmenäs M; Agarwal J; Nassim M; Živković-Gojović M; Shen Y; Dong X; Duarte M; Compton C; Vogelmeier CF; Halpin DMG
Adv Ther; 2022 Nov; 39(11):4961-5010. PubMed ID: 35857184
[TBL] [Abstract][Full Text] [Related]
7. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects.
Feldman GJ; Edin A
Ther Adv Respir Dis; 2013 Dec; 7(6):311-9. PubMed ID: 24004659
[TBL] [Abstract][Full Text] [Related]
8. Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD.
Kardos P; Worsley S; Singh D; Román-Rodríguez M; Newby DE; Müllerová H
Int J Chron Obstruct Pulmon Dis; 2016; 11():2885-2895. PubMed ID: 27932872
[TBL] [Abstract][Full Text] [Related]
9. LABA/LAMA versus LABA/ICS fixed-dose combinations in the prevention of COPD exacerbations: a modeling analysis of literature aggregate data.
Gong Y; Sui Z; Lv Y; Zheng Q; Li L
Eur J Clin Pharmacol; 2023 Oct; 79(10):1321-1332. PubMed ID: 37507595
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations.
Rogliani P; Matera MG; Ritondo BL; De Guido I; Puxeddu E; Cazzola M; Calzetta L
Pulm Pharmacol Ther; 2019 Dec; 59():101841. PubMed ID: 31520718
[TBL] [Abstract][Full Text] [Related]
11. New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectives.
Singh D
Br J Clin Pharmacol; 2015 May; 79(5):695-708. PubMed ID: 25377687
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of efficacy and safety of LABA/LAMA fixed-dose combinations in the treatment of stable COPD.
Gong Y; Lv Y; Liu H; Zheng Q; Li L
Ther Adv Respir Dis; 2022; 16():17534666211066068. PubMed ID: 35001708
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
Ridolo E; Montagni M; Riario-Sforza GG; Baroni M; Incorvaia C
Ther Adv Respir Dis; 2015 Apr; 9(2):49-55. PubMed ID: 25691493
[TBL] [Abstract][Full Text] [Related]
15. Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study.
Feldman GJ; Sousa AR; Lipson DA; Tombs L; Barnes N; Riley JH; Patel S; Naya I; Compton C; Alcázar Navarrete B
Adv Ther; 2017 Nov; 34(11):2518-2533. PubMed ID: 29094315
[TBL] [Abstract][Full Text] [Related]
16. Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease.
Babu KS; Morjaria JB
Ther Adv Respir Dis; 2015 Apr; 9(2):56-68. PubMed ID: 25754881
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: a systematic review and network meta-analysis.
Schlueter M; Gonzalez-Rojas N; Baldwin M; Groenke L; Voss F; Reason T
Ther Adv Respir Dis; 2016 Apr; 10(2):89-104. PubMed ID: 26746383
[TBL] [Abstract][Full Text] [Related]
18. New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology.
D'Urzo AD; Cazzola M; Hanania NA; Buhl R; Maleki-Yazdi MR
Int J Chron Obstruct Pulmon Dis; 2018; 13():2805-2819. PubMed ID: 30233171
[TBL] [Abstract][Full Text] [Related]
19. Chronic Obstructive Pulmonary Disease Exacerbations and Pneumonia Hospitalizations Among New Users of Combination Maintenance Inhalers.
Feldman WB; Avorn J; Kesselheim AS; Gagne JJ
JAMA Intern Med; 2023 Jul; 183(7):685-695. PubMed ID: 37213116
[TBL] [Abstract][Full Text] [Related]
20. A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease.
Muraki M; Kunita Y; Shirahase K; Yamazaki R; Hanada S; Sawaguchi H; Tohda Y
BMC Pulm Med; 2021 Jan; 21(1):26. PubMed ID: 33441146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
